GlaxoSmithKline, which is making big investments in manufacturing in the U.K., will help its homeland try to figure out how to revive its manufacturing base.
Danish medical device maker Coloplast is said to have paid $16 million to settle lawsuits claiming it injured women with vaginal-mesh inserts. With settlement talk swirling around at least 5 more makers of the plagued devices, that has some watchers saying the time may be ripe for a global settlement.
Neuromodulation devices have been key to Boston Scientific's years-long effort to reverse its lagging fortunes, and now the med tech giant has teamed up with two European nonprofits to promote its treatments for Parkinson's disease and dystonia.
Johnson & Johnson is moving ahead with its renal denervation program in the wake of Medtronic's major setback, winning CE marking for its Renlane renal denervation system, which doctors in Europe are already using to treat drug-resistant hypertension.
A European Medicines Agency committee has recommended approval for another COPD treatment from GlaxoSmithKline, setting the stage for a likely nod in the coming months as the drugmaker looks to bolster its respiratory franchise.
Biogen Idec's hot-selling multiple sclerosis drug Tecfidera has to win reimbursement in individual European countries where governments have gotten stingy about parting with healthcare dollars. A decision Thursday by U.K. price watchdog NICE is an indication of the cost hurdles to be faced.
Medtronic launched a new crossing catheter in Europe to treat peripheral artery disease. The device recently received a European CE mark, but has yet to win FDA clearance, the company said in a statement.
Development officials in Ireland are excited about the spin-off benefits of getting a Regeneron plant in Limerick. The drugmaker is excited about having a new manufacturing facility that will produce the Irish tax benefits that are all the vogue in pharma these days.
Medical device maker ConvaTec will shutter its Skillman, NJ office and lay off 118 employees from its sales, marketing and human resources division, The Star-Ledger reports.
Sorin Group offered up some unaudited results for the fourth quarter of 2013, Thursday, telling investors its net profit was up 80.3% compared to the final quarter of 2012.